Literature DB >> 29880614

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

Kathryn G Roberts1, Laura J Janke1, Yaqi Zhao1, Aman Seth2, Jing Ma1, David Finkelstein3, Steve Smith4, Kevin Ebata4, Brian B Tuch4, Stephen P Hunger5, Charles G Mullighan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29880614      PMCID: PMC6107883          DOI: 10.1182/blood-2018-05-849554

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  23 in total

Review 1.  ETV6 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Audrey Basinko; Marc De Braekeleer
Journal:  Leuk Res       Date:  2012-05-12       Impact factor: 3.156

2.  B lymphocyte-specific, Cre-mediated mutagenesis in mice.

Authors:  R C Rickert; J Roes; K Rajewsky
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

3.  Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.

Authors:  Kathryn G Roberts; Yung-Li Yang; Debbie Payne-Turner; Wenwei Lin; Jacob K Files; Kirsten Dickerson; Zhaohui Gu; Jack Taunton; Laura J Janke; Taosheng Chen; Mignon L Loh; Stephen P Hunger; Charles G Mullighan
Journal:  Blood Adv       Date:  2017-08-30

4.  Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Nidal Boulos; Heather L Mulder; Christopher R Calabrese; Jeffrey B Morrison; Jerold E Rehg; Mary V Relling; Charles J Sherr; Richard T Williams
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

Review 5.  ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.

Authors:  Chris L Lannon; Poul H B Sorensen
Journal:  Semin Cancer Biol       Date:  2005-06       Impact factor: 15.707

6.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Authors:  Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

7.  The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Authors:  Elena Ardini; Roberta Bosotti; Andrea Lombardi Borgia; Cristina De Ponti; Alessio Somaschini; Rosaria Cammarota; Nadia Amboldi; Laura Raddrizzani; Andrea Milani; Paola Magnaghi; Dario Ballinari; Daniele Casero; Fabio Gasparri; Patrizia Banfi; Nilla Avanzi; Maria B Saccardo; Rachele Alzani; Tiziano Bandiera; Eduard Felder; Daniele Donati; Enrico Pesenti; Andrea Sartore-Bianchi; Marcello Gambacorta; Marco A Pierotti; Salvatore Siena; Silvio Veronese; Arturo Galvani; Antonella Isacchi
Journal:  Mol Oncol       Date:  2014-06-12       Impact factor: 6.603

8.  The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow.

Authors:  L C Wang; W Swat; Y Fujiwara; L Davidson; J Visvader; F Kuo; F W Alt; D G Gilliland; T R Golub; S H Orkin
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

9.  Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.

Authors:  Sabine Topka; Joseph Vijai; Michael F Walsh; Lauren Jacobs; Ann Maria; Danylo Villano; Pragna Gaddam; Gang Wu; Rose B McGee; Emily Quinn; Hiroto Inaba; Christine Hartford; Ching-Hon Pui; Alberto Pappo; Michael Edmonson; Michael Y Zhang; Polina Stepensky; Peter Steinherz; Kasmintan Schrader; Anne Lincoln; James Bussel; Steve M Lipkin; Yehuda Goldgur; Mira Harit; Zsofia K Stadler; Charles Mullighan; Michael Weintraub; Akiko Shimamura; Jinghui Zhang; James R Downing; Kim E Nichols; Kenneth Offit
Journal:  PLoS Genet       Date:  2015-06-23       Impact factor: 5.917

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more
  16 in total

1.  Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry.

Authors:  Laura J Janke; Charles G Mullighan; Jinjun Dang; Jerold E Rehg
Journal:  Vet Pathol       Date:  2019-06-06       Impact factor: 2.221

2.  Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Authors:  Ilaria Iacobucci; Ji Wen; Manja Meggendorfer; John K Choi; Lei Shi; Stanley B Pounds; Catherine L Carmichael; Katherine E Masih; Sarah M Morris; R Coleman Lindsley; Laura J Janke; Thomas B Alexander; Guangchun Song; Chunxu Qu; Yongjin Li; Debbie Payne-Turner; Daisuke Tomizawa; Nobutaka Kiyokawa; Marcus Valentine; Virginia Valentine; Giuseppe Basso; Franco Locatelli; Eric J Enemark; Shirley K Y Kham; Allen E J Yeoh; Xiaotu Ma; Xin Zhou; Edgar Sioson; Michael Rusch; Rhonda E Ries; Elliot Stieglitz; Stephen P Hunger; Andrew H Wei; L Bik To; Ian D Lewis; Richard J D'Andrea; Benjamin T Kile; Anna L Brown; Hamish S Scott; Christopher N Hahn; Paula Marlton; Deqing Pei; Cheng Cheng; Mignon L Loh; Benjamin L Ebert; Soheil Meshinchi; Torsten Haferlach; Charles G Mullighan
Journal:  Nat Genet       Date:  2019-03-29       Impact factor: 38.330

Review 3.  How advanced are we in targeting novel subtypes of ALL?

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2019-10-18       Impact factor: 3.020

4.  Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.

Authors:  Denis M Schewe; Lennart Lenk; Fotini Vogiatzi; Dorothee Winterberg; Annika V Rademacher; Swantje Buchmann; Dahlia Henry; Anke K Bergmann; Gunnar Cario; Michael C Cox
Journal:  Blood Adv       Date:  2019-11-26

Review 5.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

Review 6.  Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?

Authors:  Thai Hoa Tran; Sarah K Tasian
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

Review 7.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

8.  Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.

Authors:  Valentina Nardi; Nora Ku; Matthew J Frigault; Adrian M Dubuc; Harrison Kwei Tsai; Philip C Amrein; Gabriela S Hobbs; Andrew M Brunner; Rupa Narayan; Meghan E Burke; Julia Foster; Paola Dal Cin; Marcela V Maus; Amir T Fathi; Hanno Hock
Journal:  Blood Adv       Date:  2020-01-14

9.  Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.

Authors:  Maximilian Schieck; Jana Lentes; Kathrin Thomay; Winfried Hofmann; Yvonne Lisa Behrens; Maike Hagedorn; Juliane Ebersold; Colin F Davenport; Grazia Fazio; Anja Möricke; Swantje Buchmann; Julia Alten; Gunnar Cario; Martin Schrappe; Anke Katharina Bergmann; Martin Stanulla; Doris Steinemann; Brigitte Schlegelberger; Giovanni Cazzaniga; Gudrun Göhring
Journal:  Ann Hematol       Date:  2020-02-20       Impact factor: 3.673

Review 10.  Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Kathryn G Roberts
Journal:  Genes (Basel)       Date:  2021-05-01       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.